Document is current
Any future updates will be listed below
-
Authors
Telford, Erica
Grinsztejn, Beatriz
Olsen, Inge Christoffer https://orcid.org/0000-0001-6889-5873
Pulik, Nicolas
Mentré, France
Haviari, Skerdi
Hentzien, Maxime https://orcid.org/0000-0003-2729-9420
Ségéral, Olivier
Ekkelenkamp, Miquel B.
Ogoina, Dimie https://orcid.org/0000-0002-2098-6300
Strub-Wourgaft, Nathalie
Diallo, Alpha
Yazdanpanah, Yazdan
Calmy, Alexandra
-
Funding
Funding for this research was provided by:
European Commission (101115188)
European Commission (101115188)
European Commission (101115188)
European Commission (101115188)
European Commission (101115188)
European Commission (101115188)
European Commission (101115188)
European Commission (101115188)
European Commission (101115188)
- License Information
-
More Information
Article History
First Online: 30 June 2023
Competing interests
: M.H. received travel fees and/or honorary for lectures from Gilead Science, ViiV Healthcare, Mylan, MSD and Menarini in the past 3 years. Y.Y. has been a board member receiving consultancy fees from AbbVie, BMS, Gilead, MSD, J&J, Pfizer and ViiV Healthcare; all of these activities stopped in the past 4 years. All other authors declare no conflicts.
